US20040033228A1 - Formulation of human antibodies for treating TNF-alpha associated disorders - Google Patents

Formulation of human antibodies for treating TNF-alpha associated disorders Download PDF

Info

Publication number
US20040033228A1
US20040033228A1 US10/222,140 US22214002A US2004033228A1 US 20040033228 A1 US20040033228 A1 US 20040033228A1 US 22214002 A US22214002 A US 22214002A US 2004033228 A1 US2004033228 A1 US 2004033228A1
Authority
US
United States
Prior art keywords
antibody
formulation
mg
lt
gt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/222,140
Inventor
Hans-Juergen Krause
Lisa Baust
Michael Dickes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotechnology Ltd
Original Assignee
Abbott Biotech Ltd Bermuda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Application filed by Abbott Biotech Ltd Bermuda filed Critical Abbott Biotech Ltd Bermuda
Priority to US10/222,140 priority Critical patent/US20040033228A1/en
Assigned to ABBOTT BIOTECHNOLOGY LTD. reassignment ABBOTT BIOTECHNOLOGY LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAUST, LISA, DICKES, MICHAEL, KRAUSE, HANS-JUERGEN
Publication of US20040033228A1 publication Critical patent/US20040033228A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31714885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040033228(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Assigned to ABBVIE BIOTECHNOLOGY LTD. reassignment ABBVIE BIOTECHNOLOGY LTD. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ABBOTT BIOTECHNOLOGY LTD.
Abandoned legal-status Critical Current

Links